Antioxidants · 2024 · 20 citations · 46 references
Life SciencesNeurosciencePharmacologyEthnobotanyNeurochemistryNeuropharmacologyEssential Oil PlantsMedicinal Plant KnowledgeMedicinal PlantsNeuroprotectionOxidative Stress In NeurotoxicityParkinson DiseaseBioactive Plant CompoundsEssential Oil AntioxidantsNeuroactive Natural ProductsOxidative Stress InjuryParkinson's Disease ModelsPlant-based Food ProductsPlant-derived Natural ProductsReactive Oxygen Species Generation
Parkinson’s disease is one of the most prevalent neurological disorders affecting millions of people worldwide. There is a growing demand for novel and natural substances as complementary therapies. Essential oils and their various compounds are highly investigated natural plant-based products as potential treatment options for common human diseases, such as microbial infections, chronic diseases, and neurodegenerative disorders. The present study focuses on the beneficial effects of linalool and geraniol, the major compounds of lavender (Lavandula angustifolia L.) and geranium (Pelargonium graveolens L’Hér. in Aiton) essential oils, on oxidative stress, inflammation, and iron metabolism of the rotenone and 6-hydroxydopamine-induced in vitro Parkinson’s models. The experiments were carried out on all-trans retinoic acid differentiated SH-SY5Y cells. The effects of linalool and geraniol were compared to rasagiline, an MAO-B inhibitor. The results revealed that both essential oil compounds reduce the level of reactive oxygen species and alter the antioxidant capacity of the cells. They lower the secretion of IL-6, IL-8, and IL-1β pro-inflammatory cytokines. Moreover, linalool and geraniol change the expression of iron-related genes, such as the iron importer transferrin receptor 1, heme-oxygenase-1, and ferroportin iron exporter, and influence the intracellular iron contents. In addition, it has been unveiled that iron availability is concatenated with the actions of the essential oil compounds. Based on the results, linalool and geraniol are vigorous candidates as an alternative therapy for Parkinson’s disease.
46
NF-κB signaling in inflammation
Ting Liu, Lingyun Zhang, Donghyun Joo et al. · Signal Transduction and Targeted Therapy · 2017 · 8.1K citations · Full text
Life Sciences, Immunology, Pathology +17
Mechanism of Toxicity in Rotenone Models of Parkinson's Disease
Todd Sherer, Ranjita Betarbet, Claudia Testa et al. · Journal of Neuroscience · 2003 · 1.1K citations · Full text
Anne‐Laure Mahul‐Mellier, Johannes Burtscher, Niran Maharjan et al. · Proceedings of the National Academy of Sciences · 2020 · 751 citations · Full text
Trial of Cinpanemab in Early Parkinson’s Disease
Anthony E. Lang, Andrew Siderowf, Eric A. Macklin et al. · New England Journal of Medicine · 2022 · 333 citations · Full text
Medicine, Neurology, Pharmacotherapy +17